Literature DB >> 6636261

Automated fluorescence polarization immunoassay for monitoring vancomycin.

K S Schwenzer, C H Wang, J P Anhalt.   

Abstract

We have extended fluorescence polarization immunoassay (FPIA) technology for the measurement of drugs to include the complex amphoteric glycopeptide antibiotic vancomycin (molecular weight, 1,449). Fluorescein-labeled vancomycin was employed as a tracer, and antisera specific for vancomycin were raised in rabbits by conventional procedures. Tracer, sample, and diluted antiserum were combined, and the polarization of tracer fluorescence is determined in a specially designed fluorometer (Abbott TDx). Because of instrument design, the possibility of fluorescent interferences is minimized. The assay can measure as little as 0.6 mg/L of vancomycin and is free of interferences from hemolysis, lipemia, bilirubin, and changes in protein concentration. The coefficient of variation within assay was 3% (n = 5) and between assays was 5% (n = 5). The FPIA assay (TDx Vancomycin) was compared to a liquid chromatographic (LC) assay for vancomycin and to a commercially available radioimmunoassay (RIA) for 98 clinical specimens. A linear least-squares regression analysis gave a correlation coefficient for LC of 0.980 from the equation FPIA = 1.09 LC + 3.04, and a correlation coefficient for RIA of 0.957 from the equation FPIA = 1.036 RIA + 1.66.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6636261     DOI: 10.1097/00007691-198309000-00017

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  27 in total

1.  Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis.

Authors:  G W Kaatz; S M Seo; J R Aeschlimann; H H Houlihan; R C Mercier; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

2.  Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit.

Authors:  J Albanèse; M Léone; B Bruguerolle; M L Ayem; B Lacarelle; C Martin
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

3.  Pharmacokinetics and serum bactericidal activity of vancomycin alone and in combination with ceftazidime in healthy volunteers.

Authors:  M Boeckh; H Lode; K Borner; G Höffken; J Wagner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

4.  Single- and combination-antibiotic therapy for experimental endocarditis caused by methicillin-resistant Staphylococcus aureus.

Authors:  A Rodríguez; M V Vicente; T Olay
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

5.  Vancomycin Serum Concentration Monitoring : The Middle Ground is Best.

Authors:  F Marra; B Cairns; P Jewesson
Journal:  Clin Drug Investig       Date:  1996-08       Impact factor: 2.859

6.  Laboratory evaluation of five assay methods for vancomycin: bioassay, high-pressure liquid chromatography, fluorescence polarization immunoassay, radioimmunoassay, and fluorescence immunoassay.

Authors:  M A Pfaller; D J Krogstad; G G Granich; P R Murray
Journal:  J Clin Microbiol       Date:  1984-09       Impact factor: 5.948

Review 7.  Clinical pharmacokinetics of vancomycin.

Authors:  G R Matzke; G G Zhanel; D R Guay
Journal:  Clin Pharmacokinet       Date:  1986 Jul-Aug       Impact factor: 6.447

8.  Development of resistance to fleroxacin during therapy of experimental methicillin-susceptible Staphylococcus aureus endocarditis.

Authors:  G W Kaatz; S M Seo; S L Barriere; L M Albrecht; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

9.  Cellular pharmacokinetics and pharmacodynamics of the glycopeptide antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages.

Authors:  Françoise Van Bambeke; Stéphane Carryn; Cristina Seral; Hugues Chanteux; Donatienne Tyteca; Marie-Paule Mingeot-Leclercq; Paul M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

10.  Comparative prophylactic efficacies of ciprofloxacin, ofloxacin, cefazolin, and vancomycin in experimental model of staphylococcal wound infection.

Authors:  D S Kernodle; A B Kaiser
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.